{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:tecaginlimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:mecbotamab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02898753: Phase 1/Phase 2 Interventional Terminated Pompe Disease
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:anzurstobart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:prolgolimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:redipultide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03828747: Phase 2 Interventional Completed Alzheimer's Disease
(2019)
Source URL:
Class:
PROTEIN